Study for Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma

Gender PreferenceNone
Age Group18 - 99 years
Research Start DateOctober 1, 2012
Research End DateOctober 1, 2022
Principal InvestigatorAhmad Wehbe, MD
Description

Multicenter Phase II Study of MK-2206 in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma

Participants in this research study have been diagnosed with advanced nasopharyngeal cancer. The purpose of this research study is to find out what effects, good and/or bad, an investigational drug called MK-2206 has on the participant and the nasopharyngeal cancer. Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. Study involvement will last for approximately 3 years.

Contact Info

Cindy Robertson, 319-356-2778

Keywordsspan itemProp='description'>cancer ; head and neck ; IRB#201208779 ; metastatic nasopharyngeal carcinoma ; MK-2206 ; nasopharynx ; neoplasms ; phase 2 ; phase II ; squamous cell ; stage IV ; wehbe ;